– UK, Cambridge – Abcam plc (LON: ABC | Nasdaq: ABCM), a global leader in the supply of life science research tools, today announced the appointment of Sally Crawford to its Board as a non-executive Director with immediate effect.
“I am delighted to welcome Sally to the Board of Abcam. Sally has had a distinguished career in the healthcare industry and her experience and expertise, particularly her understanding of biopharma and diagnostic customers, will be a valuable asset to the Company as we continue to partner in this area and work towards our long-term growth plans.” said Board Chairman, Peter Allen.
Sally will join the Remuneration Committee (as Chair designate) and the Audit and Risk Committee.
About Sally Crawford
Sally Crawford has held several senior leadership and board positions in the healthcare industry spanning more than three decades. She served as COO of Healthsource Inc., a publicly held managed care organization, from its founding in April 1985 until January 1997. During her tenure at Healthsource, she led the development of the operating systems and marketing strategies and supported strategic alliances across the industry.
Since January 1997, Sally has been a healthcare consultant in New Hampshire, US, for clients such as Bayer Healthcare Diabetes Division, as well as healthcare investors, providers, regulators, and managed care payers.
Sally has extensive board experience and currently serves on the board of directors of Hologic, Inc., Insulet Corporation, and Prolacta Bioscience. She is the current Compensation Chair at Insulet Corporation and Prolacta Bioscience and former Compensation Chair at Hologic.
Previously Sally served on the boards of Exact Sciences, CombinatoRx Inc., Zalicus Inc., Chittenden Corporation, Cytyc Corporation (which merged with Hologic, Inc. in October 2007), and Universal American.
About Abcam plc
As an innovator in reagents and tools, Abcam’s purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated antibodies, assays, and other research tools to address important targets in critical biological pathways.
Already a pioneer in data sharing and eCommerce in the life sciences, Abcam’s ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health.
Abcam’s worldwide customer base of approximately 750,000 life science researchers uses Abcam’s antibodies, reagents, biomarkers, and assays. By actively listening to and collaborating with these researchers, the Company continuously advances its portfolio to address their needs. A transparent program of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.
Founded in 1998 and headquartered in Cambridge, UK, the Company has served customers in more than 130 countries. Abcam’s ordinary shares are listed on the London Stock Exchange (LON: ABC) and its American Depositary Shares trade on the Nasdaq Global Market (Nasdaq: ABCM).
For more information: https://www.abcam.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
